CART-19 cells (Henan Hualong Biotechnology)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCART-19 cells (Henan Hualong Biotechnology)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLeukemia, Lymphoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHenan Hualong Biotechnology
China Registration ClassN/A

Develop Information

Active CompaniesHenan Hualong Biotechnology
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A